Published in Hepatitis Weekly, June 18th, 2007
"Patients with mild hepatitis C recurrence (fibrosis stage F0 to F2, n=54) were randomized to no treatment (group A, n=27) or peginterferon alfa-2b/ribavirin for 48 weeks (group B, n=27). Patients with severe recurrence (F3 to F4, cholestatic hepatitis)...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Hepatitis Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.